Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Hormone, Biologic therapy.

University of Liverpool, Liverpool, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Liverpool
Treatments:Hormone, Biologic therapyHospital:University of Liverpool
Drugs:Journal:Link
Date:May 2012

Description:

Patients:
This study involved 39 chronic lymphocytic leukemia patients who had a genetic deletion of the TP53 gene. The median patient age was 62 years and 56% were male.

Treatment:
Patients were threated with the biologic therapy agent called alemtuzumab, which is an anti-CD52 monoclonal antibody that targets cancer cells to be killed by the immune system. Patients were also treated with the corticosteroid (hormone) methylprednisolone.

Toxicities:
Treatment-related deaths due to infection and brain hemorrhage were reported. Grade 4 neutropenia and grade 3 fatigue were also reported.

Results:
The median overall survival was 23.5 months.

Support:
This study was partially supported by Bayer-Schering Pharma.

Correspondence: Dr. Andrew Pettitt, email: [email protected]



Back